LeonaBio (LONA) Registration Filing summary

Company overview and business model

• Focuses on developing small molecules to restore neuronal health and slow neurodegeneration, targeting the neurotrophic HGF system to enhance brain and nervous system function.

• Pipeline includes novel compounds designed to cross the blood-brain barrier or act in the peripheral nervous system.

• Incorporated in 2011, converted to a Delaware corporation in 2015, with headquarters in Bothell, Washington.

Use of proceeds and capital allocation

• Net proceeds are expected to be used for working capital and general corporate purposes.

• May allocate funds to acquire, license, or invest in complementary products, technologies, or businesses, though no current agreements exist.

• Pending use, proceeds may be invested in short-term, interest-bearing instruments or U.S. government obligations.

Risk factors and disclosures

• Investment involves a high degree of risk, with detailed risk factors provided in the prospectus supplement and incorporated SEC filings.

• Risks include those described in the most recent Annual and Quarterly Reports, as well as additional risks that may arise.

• Forward-looking statements are subject to uncertainties and actual results may differ materially.